MDT-AP-1156
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 21.96
- os_event
- true
- age_years
- 5.7
- sex
- M
- new_clusters
- C1
- umap1_2d
- 3.91379136
- umap2_2d
- 0.465367086
- umap1_3d
- -0.152547812
- umap2_3d
- -3.480303496
- umap3_3d
- -0.91565681
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.280
- MYC_TARGETS_V2+0.270
- MTORC1_SIGNALING+0.260
- WNT_BETA_CATENIN_SIGNALING+0.200
- G2M_CHECKPOINT+0.190
- KRAS_SIGNALING_DN+0.190
- E2F_TARGETS+0.180
- TGF_BETA_SIGNALING+0.160
- UV_RESPONSE_UP+0.110
- APICAL_SURFACE+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.370
- INTERFERON_GAMMA_RESPONSE-0.370
- COMPLEMENT-0.350
- INFLAMMATORY_RESPONSE-0.320
- INTERFERON_ALPHA_RESPONSE-0.250
- KRAS_SIGNALING_UP-0.230
- UV_RESPONSE_DN-0.200
- ANDROGEN_RESPONSE-0.180
- TNFA_SIGNALING_VIA_NFKB-0.180
- HEDGEHOG_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0360 | Med | Medulloblastoma | 0.771 |
| 2 | MDT-AP-3185 | Med | Medulloblastoma | 0.742 |
| 3 | SRR8518139 | — | E | 0.733 |
| 4 | MDT-AP-0514 | Med | Medulloblastoma | 0.720 |
| 5 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.718 |
| 6 | TCGA-77-8140-01A-11R-2247-07 | — | cohortSQ1 | 0.716 |
| 7 | GSM6454731 | — | E | 0.714 |
| 8 | TCGA-NC-A5HT-01A-11R-A26W-07 | — | cohortSQ1 | 0.714 |
| 9 | BS_0HW7W7SD | Embryonal tumors | — | 0.713 |
| 10 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.711 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |